• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中东老年房颤患者的人口统计学和风险特征:约旦房颤研究(JoFib)。

Demographics and Risk Profile of Elderly Middle Eastern Patients with Atrial Fibrillation: The Jordan Atrial Fibrillation (JoFib) Study.

机构信息

Department of Medicine, MedStar Union Memorial Hospital, Baltimore, MD, USA.

Cardiology Department, Istishari Hospital, Amman, Jordan.

出版信息

Vasc Health Risk Manag. 2022 Apr 15;18:289-295. doi: 10.2147/VHRM.S360822. eCollection 2022.

DOI:10.2147/VHRM.S360822
PMID:35449533
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9017703/
Abstract

BACKGROUND

Atrial fibrillation (AF) is the most common arrhythmia that is associated with high morbidity and mortality. The prevalence of AF increases with age and the elderly constitute a vulnerable cohort for higher stroke and bleeding complications.

METHODS

A total of 2163 adult consecutive patients with AF in 19 hospitals and 11 outpatient clinics in Jordan were enrolled in the Jordan AF study from May 2019 to January 2021. The clinical characteristics, demographics, and risk profiles of the elderly patients (≥80 years old) were compared to the younger patients (<80 years old).

RESULTS

Of 2163 patients, 379 (17.5%) constituted the elderly group. The elderly group had higher prevalence of hypertension (79.9% vs 73.5%, p=0.01), lower prevalence of smoking (5.0% vs 15.2%, p<0.001) and lower body mass index (28.1 ± 5.5 kg/m vs 29.8 ± 6.2 kg/m, p<0.001) compared with younger patients. They also had more strokes or systemic emboli (25.6% vs 14.7%, p<0.001), heart failure (30.3% vs 22.9%, p=0.002), pulmonary hypertension (30.6% vs 24.8%, p=0.02), and chronic kidney disease (13.5% vs 8.3%, p=0.002). The elderly cohort had higher mean CHA2DS2-VASc (5.0 ± 1.5 vs 3.6 ± 1.8, p<0.001) and HAS-BLED scores (2.2 ± 1.1 vs 1.5 ± 1.1, p<0.001) compared to younger group. Among 370 elderly with non-valvular AF (NVAF), oral anticoagulant agents (OACs) were prescribed for 278 (84.2%) of eligible high-risk patients. Of the 1402 younger patients with NVAF, OACs were prescribed for 1133 (84.3%) of eligible patients. Direct oral anticoagulant agents (DOACs) were more frequently used in the elderly compared to the young (72.3% vs 62.3%, p<0.001).

CONCLUSION

Elderly Middle Eastern AF patients have worse baseline clinical profiles and higher risk scores compared to younger patients. The majority of the elderly were prescribed guideline directed OACs, with higher use of DOACs than the younger cohort.

CLINICAL STUDIES REGISTRATION

The study is registered on clinicaltrials.gov (unique identifier number NCT03917992).

摘要

背景

心房颤动(AF)是最常见的心律失常,与高发病率和死亡率相关。AF 的患病率随年龄增长而增加,老年人是中风和出血并发症风险较高的脆弱群体。

方法

2019 年 5 月至 2021 年 1 月,在约旦的 19 家医院和 11 家门诊诊所共纳入了 2163 例连续的成年 AF 患者,这些患者参与了约旦 AF 研究。比较了年龄≥80 岁的老年患者与年龄<80 岁的年轻患者的临床特征、人口统计学和风险特征。

结果

在 2163 例患者中,379 例(17.5%)为老年组。与年轻患者相比,老年组高血压患病率更高(79.9% vs 73.5%,p=0.01),吸烟率更低(5.0% vs 15.2%,p<0.001),体重指数(BMI)更低(28.1 ± 5.5 kg/m2 vs 29.8 ± 6.2 kg/m2,p<0.001)。此外,老年患者中风或全身性栓塞(25.6% vs 14.7%,p<0.001)、心力衰竭(30.3% vs 22.9%,p=0.002)、肺动脉高压(30.6% vs 24.8%,p=0.02)和慢性肾脏病(13.5% vs 8.3%,p=0.002)的发生率更高。与年轻组相比,老年组的平均 CHA2DS2-VASc 评分(5.0 ± 1.5 vs 3.6 ± 1.8,p<0.001)和 HAS-BLED 评分(2.2 ± 1.1 vs 1.5 ± 1.1,p<0.001)更高。在 370 例非瓣膜性心房颤动(NVAF)的老年患者中,有 278 例(84.2%)高危患者接受了口服抗凝剂(OAC)治疗。在 1402 例年轻的 NVAF 患者中,有 1133 例(84.3%)符合条件的患者接受了 OAC 治疗。与年轻患者相比,老年患者更常使用直接口服抗凝剂(DOAC)(72.3% vs 62.3%,p<0.001)。

结论

与年轻患者相比,中东地区的老年 AF 患者基线临床特征更差,风险评分更高。大多数老年患者接受了指南推荐的 OAC 治疗,与年轻患者相比,老年患者使用 DOAC 的比例更高。

临床试验注册

该研究在 clinicaltrials.gov 上注册(唯一标识符 NCT03917992)。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7bdd/9017703/51f60146d1ad/VHRM-18-289-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7bdd/9017703/31280cfa6d33/VHRM-18-289-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7bdd/9017703/51f60146d1ad/VHRM-18-289-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7bdd/9017703/31280cfa6d33/VHRM-18-289-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7bdd/9017703/51f60146d1ad/VHRM-18-289-g0002.jpg

相似文献

1
Demographics and Risk Profile of Elderly Middle Eastern Patients with Atrial Fibrillation: The Jordan Atrial Fibrillation (JoFib) Study.中东老年房颤患者的人口统计学和风险特征:约旦房颤研究(JoFib)。
Vasc Health Risk Manag. 2022 Apr 15;18:289-295. doi: 10.2147/VHRM.S360822. eCollection 2022.
2
Adherence to the 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline on the Use of Oral Anticoagulant Agents in Middle Eastern Patients with Atrial Fibrillation: The Jordan Atrial Fibrillation (JoFib) Study.遵循2019年美国心脏协会/美国心脏病学会/美国心律学会对2014年美国心脏协会/美国心脏病学会/美国心律学会关于中东地区房颤患者口服抗凝剂使用指南的重点更新:约旦房颤(JoFib)研究。
Int J Vasc Med. 2021 Apr 8;2021:5515089. doi: 10.1155/2021/5515089. eCollection 2021.
3
The Intersection of Atrial Fibrillation and Coronary Artery Disease in Middle Eastern Patients. Analysis from the Jordan Atrial Fibrillation Study.中东患者中心房颤动与冠状动脉疾病的交叉。来自约旦心房颤动研究的分析。
Glob Heart. 2024 Mar 12;19(1):29. doi: 10.5334/gh.1312. eCollection 2024.
4
Validation of CHA2DS2 VASc Score Predictability of Stroke and Systemic Embolization in a Middle Eastern Population with AF: The Jordan Atrial Fibrillation (JoFib) Study.CHA2DS2 VASc 评分对中东人群 AF 中卒中及系统性栓塞预测价值的验证:约旦心房颤动(JoFib)研究。
Vasc Health Risk Manag. 2023 Apr 24;19:255-264. doi: 10.2147/VHRM.S404575. eCollection 2023.
5
Paroxysmal and Non-Paroxysmal Atrial Fibrillation in Middle Eastern Patients: Clinical Features and the Use of Medications. Analysis of the Jordan Atrial Fibrillation (JoFib) Study.中东患者的阵发性和非阵发性心房颤动:临床特征和药物使用。约旦心房颤动(JoFib)研究分析。
Int J Environ Res Public Health. 2022 May 19;19(10):6173. doi: 10.3390/ijerph19106173.
6
Stroke and bleeding risk scores in patients with atrial fibrillation and valvular heart disease: evaluating 'valvular heart disease' in a nationwide cohort study.心房颤动和心脏瓣膜病患者的卒中与出血风险评分:在全国范围内队列研究中评估“心脏瓣膜病”。
Europace. 2019 Jan 1;21(1):33-40. doi: 10.1093/europace/euy151.
7
One-Year Clinical Outcome in Middle Eastern Patients with Atrial Fibrillation: The Jordan Atrial Fibrillation (JoFib) Study.中东地区心房颤动患者的一年临床结局:约旦心房颤动(JoFib)研究
Int J Vasc Med. 2022 Apr 13;2022:4240999. doi: 10.1155/2022/4240999. eCollection 2022.
8
Real-World Clinical Characteristics and Treatment Patterns of Individuals Aged 80 and Older with Nonvalvular Atrial Fibrillation: Results from the ReAl-life Multicenter Survey Evaluating Stroke Study.80岁及以上非瓣膜性心房颤动患者的真实世界临床特征和治疗模式:评估卒中研究的真实生活多中心调查结果
J Am Geriatr Soc. 2017 Aug;65(8):1684-1690. doi: 10.1111/jgs.14855. Epub 2017 Apr 10.
9
Age-Related Differences in the Clinical Characteristics and Treatment of Elderly Patients With Atrial Fibrillation in Japan - Insight From the ANAFIE (All Nippon AF In Elderly) Registry.日本老年心房颤动患者的临床特征和治疗的年龄相关性差异 - 来自 ANAFIE(日本老年房颤)登记研究的见解。
Circ J. 2020 Feb 25;84(3):388-396. doi: 10.1253/circj.CJ-19-0898. Epub 2020 Jan 23.
10
Causes of Ischemic Stroke in Patients with Non-Valvular Atrial Fibrillation.非瓣膜性心房颤动患者缺血性卒中的病因
Cerebrovasc Dis. 2016;42(3-4):196-204. doi: 10.1159/000445723. Epub 2016 Apr 26.

引用本文的文献

1
New-Onset Atrial Fibrillation Following Isolated Coronary Artery Bypass Grafting: Is Pulmonary Hypertension a Risk Factor?单纯冠状动脉旁路移植术后新发心房颤动:肺动脉高压是危险因素吗?
Braz J Cardiovasc Surg. 2025 Aug 26;40(5):e20240352. doi: 10.21470/1678-9741-2024-0352.
2
The Atrial FibriLlatiOn Registry (FLOW-AF): Patient Characteristics, Treatment Patterns, and Outcomes in Egypt.心房颤动注册研究(FLOW-AF):埃及患者的特征、治疗模式及结局
Cardiol Ther. 2025 Jun;14(2):161-182. doi: 10.1007/s40119-025-00400-0. Epub 2025 Mar 21.
3
The one-year incidence of stroke in patients with atrial fibrillation in Jordan and its associated factors.

本文引用的文献

1
Antithrombotic treatment pattern in newly diagnosed atrial fibrillation patients and 2-year follow-up results for dabigatran-treated patients in the Africa/Middle-East Region: Phase II results from the GLORIA-AF registry program.非洲/中东地区新诊断房颤患者的抗栓治疗模式及达比加群治疗患者的2年随访结果:GLORIA-AF注册研究项目的II期结果
Int J Cardiol Heart Vasc. 2021 Apr 10;34:100763. doi: 10.1016/j.ijcha.2021.100763. eCollection 2021 Jun.
2
Adherence to the 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline on the Use of Oral Anticoagulant Agents in Middle Eastern Patients with Atrial Fibrillation: The Jordan Atrial Fibrillation (JoFib) Study.遵循2019年美国心脏协会/美国心脏病学会/美国心律学会对2014年美国心脏协会/美国心脏病学会/美国心律学会关于中东地区房颤患者口服抗凝剂使用指南的重点更新:约旦房颤(JoFib)研究。
Int J Vasc Med. 2021 Apr 8;2021:5515089. doi: 10.1155/2021/5515089. eCollection 2021.
3
约旦房颤患者中风的一年发病率及其相关因素。
Front Med (Lausanne). 2024 Jul 29;11:1408249. doi: 10.3389/fmed.2024.1408249. eCollection 2024.
Age-Related Differences in the Clinical Characteristics and Treatment of Elderly Patients With Atrial Fibrillation in Japan - Insight From the ANAFIE (All Nippon AF In Elderly) Registry.日本老年心房颤动患者的临床特征和治疗的年龄相关性差异 - 来自 ANAFIE(日本老年房颤)登记研究的见解。
Circ J. 2020 Feb 25;84(3):388-396. doi: 10.1253/circj.CJ-19-0898. Epub 2020 Jan 23.
4
Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge.心房颤动的全球流行病学:日益严重的流行趋势及公共卫生挑战。
Int J Stroke. 2021 Feb;16(2):217-221. doi: 10.1177/1747493019897870. Epub 2020 Jan 19.
5
Epidemiology of atrial fibrillation in northeast China: a cross-sectional study, 2017-2019.中国东北地区心房颤动的流行病学:一项 2017-2019 年的横断面研究。
Heart. 2020 Apr;106(8):590-595. doi: 10.1136/heartjnl-2019-315397. Epub 2019 Oct 13.
6
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.2019年美国心脏协会/美国心脏病学会/心律学会对2014年美国心脏协会/美国心脏病学会/心律学会心房颤动患者管理指南的聚焦更新:美国心脏病学会/美国心脏协会临床实践指南工作组和心律学会的报告
J Am Coll Cardiol. 2019 Jul 9;74(1):104-132. doi: 10.1016/j.jacc.2019.01.011. Epub 2019 Jan 28.
7
Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation.新发心房颤动患者的死亡、卒中和全身性栓塞以及大出血的早期风险。
Circulation. 2019 Feb 5;139(6):787-798. doi: 10.1161/CIRCULATIONAHA.118.035012.
8
Heartbeat: The worldwide burden of atrial fibrillation.心跳:心房颤动的全球负担。
Heart. 2018 Dec;104(24):1987-1988. doi: 10.1136/heartjnl-2018-314443.
9
Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis.口服抗凝药预防心房颤动患者卒中:系统评价、网状Meta分析及成本效益分析
BMJ. 2017 Nov 28;359:j5058. doi: 10.1136/bmj.j5058.
10
Global, Regional, and National Burden of Rheumatic Heart Disease, 1990-2015.全球、地区和国家风湿性心脏病负担,1990-2015 年。
N Engl J Med. 2017 Aug 24;377(8):713-722. doi: 10.1056/NEJMoa1603693.